Paradoxically, HER2 mutations are not considered to be the main driver of genetic alterations to override tumour aggressiveness, unlike in other malignancies, such as NSCLC and colorectal carcinomas [30–34]. The gene discussed is ERBB2; the disease is colorectal carcinoma.